Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.47 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | PSEN1 | P49768 | 8/20 | 0.40 |
| ▸ | TTPA | P49638 | 2/20 | 0.33 |
| ▸ | BCHE | P06276 | 4/20 | 0.33 |
| ▸ | ACHE | P22303 | 4/20 | 0.33 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.33 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2597432 | 0.87 | PTGS1 (0.62) | PTGS1PTGS2CYP1A2CYP3A4TSHR | |
| SCHEMBL23961349 | 0.87 | PTGS1 (0.48) | PTGS1PTGS2CYP1A2CYP3A4TSHR | |
| SCHEMBL20819462 | 0.83 | PTGS1 (0.45) | PTGS1PTGS2CYP1A2CYP3A4TSHR | |
| SCHEMBL10071787 | 0.83 | PTGS1 (0.45) | PTGS1PTGS2CYP1A2CYP3A4TSHR | |
| SCHEMBL15150900 | 0.81 | PSEN1 (0.47) | PTGS1PTGS2CYP1A2CYP3A4TSHR | |
| SCHEMBL837194 | 0.79 | HPGD (0.37) | PTGS1PTGS2CYP1A2CYP3A4TSHR | |
| SCHEMBL5460830 | 0.78 | PTGS1 (0.36) | PTGS1PTGS2CYP1A2CYP3A4TSHR | |
| SCHEMBL29242853 | 0.78 | PSEN1 (0.53) | PTGS1PTGS2CYP1A2CYP3A4TSHR | |
| SCHEMBL14938837 | 0.78 | PTGS1 (0.76) | PTGS1PTGS2CYP1A2CYP3A4TSHR | |
| SCHEMBL2059274 | 0.78 | PTGS1 (0.76) | PTGS1PTGS2CYP1A2CYP3A4TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3733642-B1 | 4-(P-QUINONYL)-2-HYDROXYBUTANAMIDE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES | PTC THERAPEUTICS INC (US) | 2024-05-08 | — | — | EP | disclosed |
| US-20210227822-A1 | COMPOUNDS FOR PROTECTION OF CELLS | SULFATEQ B.V. (NL) | 2021-07-29 | — | — | US | disclosed |
| EP-1233962-A2 | NOVEL HETEROCYCLIC COMPOUNDS AND THEIR USE AS MEDICINES | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2002-08-28 | — | — | EP | disclosed |
| WO-2001032654-A2 | NOVEL HETEROCYCLIC COMPOUNDS AND THEIR USE AS MEDICINES | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2001-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210227822-A1 | COMPOUNDS FOR PROTECTION OF CELLS | CASP10, BAX, CASP9 | PTGS1 1184/4885PTGS2 1395/4885CYP1A2 3066/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.